KRM Ayurveda IPO Review: A Legacy Ayurvedic Brand's Strong Public Market Debut

Quick Answer

KRM Ayurveda IPO has been a substantial winner, built around a genuinely recognised legacy healthcare brand rather than a manufactured pre-IPO story. The Delhi based Ayurvedic hospital and telemedicine company, operating under the well known Karma Ayurveda brand for kidney and chronic care, was subscribed a strong 74.27 times, and listed on 29 January 2026 at Rs 172.10, a 27.48% premium over the Rs 135 issue price. The stock has climbed further since, now trading around Rs 257, up roughly 90% from issue. The one thing worth understanding clearly: the company's revenue actually declined between FY23 and FY25 before profit jumped sharply in the final year, and growth has since decelerated further in the most recent nine months, a detail the rally has so far looked past.

KRM Ayurveda IPO Key Details at a Glance

What Does KRM Ayurveda Ltd Do?

KRM Ayurveda, incorporated in September 2019 and based in Delhi, operates under the Karma Ayurveda brand, a name with roots tracing back to 1937 in kidney and chronic disease care, now expanded into a comprehensive multispecialty Ayurvedic healthcare network. The company runs 6 hospitals and 5 clinics across India, offering in-patient and out-patient services, Panchakarma therapies and yoga programmes, alongside international telemedicine consulting reaching patients in the UK, UAE and USA.

The manufacturing and consumer arm. Beyond clinical services, the company manufactures classical and proprietary Ayurvedic medicines, nutraceuticals, capsules, tablets, syrups, oils and powders from its own facility in Kundli, Haryana, and sells a direct-to-consumer product line under the AyuKarma brand, spanning more than 300 GMP-certified products including well known items like Shilajit Resin. You can follow its live price and post listing updates on the IPO GMP Live homepage.

The strategic pivot the IPO money supports. The company is explicitly shifting from being purely a hospital chain toward a broader digital healthcare provider, using telemedicine to scale a business that would otherwise be constrained by the labour-intensive nature of physical hospitals and clinics.

How Strong Are KRM Ayurveda Financials, Really?

The revenue history is genuinely inconsistent, and this deserves more attention than the rally suggests. One reviewer explicitly flagged this as inconsistent performance: revenue actually declined from Rs 89.38 crore in FY23 to around Rs 77 crore in FY25, with a dip in between in FY24, rather than the steady growth curve investors often assume backs a strong listing.

Profit, by contrast, jumped sharply in the final year before listing. Net profit rose from Rs 3.41 crore in FY24 to Rs 12.10 crore in FY25, a roughly 255% one-year increase, arriving in the exact window used to price the IPO. This is the same pre-listing profit inflection pattern we flag across many SME reviews, though here it is paired with a genuinely strong PAT margin of 16.83% and EBITDA margin of 26.54%, both healthy figures for a hospital and wellness operator.

The nine-month FY26 numbers show continued deceleration, not confirmation. Revenue of Rs 49 crore for the period annualises to roughly Rs 65 crore, below the FY25 figure rather than above it, and profit of Rs 8.14 crore annualises to around Rs 10.85 crore, still growing versus FY24 but at a distinctly slower pace than the FY24 to FY25 jump. Unlike some names in our tracking where post-listing results confirmed the pre-IPO growth story, here the most recent evidence points toward a cooling rather than an acceleration.

Return ratios vary widely across sources, worth noting. Some pre-IPO coverage cited return on equity as high as 50.67%, while post-listing figures put it closer to 21.84%, a large discrepancy likely reflecting different calculation periods or bases. Either figure is respectable, but the wide spread itself suggests some caution in taking any single headline ratio at face value.

Why Did the Stock Rally So Strongly Despite the Revenue Inconsistency?

Several factors likely outweighed the financial history in investors' minds:

• Brand recognition carried real weight. Karma Ayurveda is not a newly invented name, it is a legacy brand with genuine heritage in kidney and chronic care dating to 1937, giving the IPO a credibility story that pure financial projections cannot manufacture.
• The wellness and Ayurveda sector tailwind is real and well documented. India's Ayurvedic healthcare market is projected to nearly double by 2030, driven by post-pandemic wellness awareness, government AYUS backing, and rising interest in alternative and preventive care, a genuine structural growth theme investors wanted exposure to.
• The telemedicine pivot offered a scalability narrative. Physical hospitals are inherently capital and labour intensive; a credible plan to scale via telemedicine and international teleconsulting gave the market a growth lever that does not require building new hospitals one at a time.
• Employee attrition improved materially, a genuine operational positive. Attrition fell from a concerning 78% in FY24 to 31% in FY25, addressing one of the more specific, quantifiable risks in a service business where continuity of medical staff directly affects patient trust and care quality.

What Are the Real Risks Here?

Beyond the revenue inconsistency and recent deceleration already discussed, a few structural risks are worth tracking:

• Geographic concentration remains heavy. Roughly 60 to 68% of revenue still comes from Delhi and Haryana, meaning any regional disruption, competitive entry, or regulatory change in those two markets would disproportionately affect results, and the international telemedicine push has yet to meaningfully diversify this.
• Insurance-linked revenue creates a cash flow drag. About 15 to 20% of revenue ties to insurance providers with payment cycles running 150 to 180 days, a real strain on working capital that the company must manage carefully as it scales.
• The asset-light, leased-premises model carries renewal risk. Most hospital and clinic premises are leased rather than owned, meaning non-renewal or unfavourable renegotiation of any key lease could disrupt operations at that location.
• Debt remains a live consideration. Total borrowings of around Rs 25 crore against a net worth of roughly Rs 36 crore is a meaningful leverage position for a company this size, even as the debt-to-equity ratio has reportedly improved.

Should You Buy KRM Ayurveda Shares Now?

The stock trades around Rs 257 against a Rs 135 issue price. The honest read by investor type:

• Conservative investors: The legacy brand and sector tailwind are genuine positives, but a revenue history that actually declined over two years, followed by a sharp pre-IPO profit jump that has since decelerated again, is a pattern that deserves real scrutiny regardless of the brand name behind it. Wait for at least the full FY26 results to see whether growth stabilises or continues cooling.
• Moderate investors: Allottees sitting on a near-doubling should seriously weigh booking partial profits, the rally has run well ahead of the underlying revenue trend, and the geographic and insurance-linked cash flow risks remain real structural features of the business.
• Aggressive investors: The brand equity, sector tailwind and telemedicine scalability story support continued interest, but entering fresh after a 90% rally on a business whose most recent quarters are decelerating, not accelerating, is a bet on the brand and theme carrying the stock further than the numbers currently justify.

Honest take. KRM Ayurveda is a case where a genuinely credible legacy brand and a real sector tailwind have carried the stock further than the underlying financial trend alone would suggest. The revenue decline from FY23 to FY25, the sharp pre-IPO profit jump, and the renewed deceleration in the nine-month FY26 numbers are all real facts sitting underneath a nearly 90% post-listing rally. The brand and theme are not empty, Karma Ayurveda has real heritage and the wellness sector has real tailwinds, but the financial trend deserves at least as much attention as the story before paying up at current levels.

Where Did the IPO Money Go?

The Rs 69.74 to 77.49 crore issue was entirely a fresh issue with no offer for sale. The largest allocations were Rs 13.67 crore for constructing and developing telemedicine operational facilities, Rs 22.90 crore for working capital, and Rs 12.50 crore for repaying or prepaying loans, directly addressing the company's debt position. Smaller allocations covered CRM software and hardware infrastructure, human resources, general corporate purposes and issue expenses. The mix of debt reduction, working capital, and telemedicine capex reflects the company's stated strategy of scaling beyond its physical hospital footprint while cleaning up its balance sheet.

Contact Details

• Company: KRM Ayurveda Ltd. (operating as Karma Ayurveda)
• Location: Delhi, with manufacturing at Kundli, Haryana; hospitals and clinics across India plus international telemedicine reach (UK, UAE, USA)
• Business: Multispecialty Ayurvedic hospitals and clinics, kidney and chronic disease care, Panchakarma therapies, telemedicine consulting, and the AyuKarma consumer product line
• Promoters: Puneet Dhawan, Tanya Dhawan
• Registrar: Skyline Financial Services Pvt. Ltd.
• Lead Manager: NEXGEN Financial Solutions Pvt. Ltd.
• Listing: NSE SME

This page is not investment advice. GMP is indicative only and unofficial. Please consult a SEBI registered financial advisor before investing.